“The GFINDER report shows a large retraction of public funding, especially for product development partnerships (PDPs), which will have devastating consequences for global health. As diseases such as tuberculosis continue to kill millions of people, products developed with a decade of public investment will stall in late stage development. We have made huge progress over the last 10 years and are now on the verge of delivering treatments that can potentially transform global health. Donors should view these findings as a wake-up call and work to put product development for diseases of poverty back on track. Now is a time of tremendous opportunity, with dozens of potential products within the reach of patients--donors must commit to taking them across the finish line.”
Dr. Mel Spigelman
President and CEO
TB Alliance